Association of Homocysteine and Asymmetric Dimethylarginine With Atherosclerosis and Cardiovascular Events in Maintenance Hemodialysis Patients
- 30 November 2006
- journal article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 48 (5), 797-805
- https://doi.org/10.1053/j.ajkd.2006.08.003
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Homocysteine in uraemia--a puzzling and conflicting storyNephrology Dialysis Transplantation, 2004
- Randomized Trial of Folic Acid for Prevention of Cardiovascular Events in End-Stage Renal DiseaseJournal of the American Society of Nephrology, 2004
- A Low, Rather than a High, Total Plasma Homocysteine Is an Indicator of Poor Outcome in Hemodialysis PatientsJournal of the American Society of Nephrology, 2004
- Homocysteine and Risk of Ischemic Heart Disease and StrokeJAMA, 2002
- Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patientsKidney International, 2002
- Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patientsKidney International, 2000
- Plasma Total Homocysteine and Hemodialysis Access ThrombosisJournal of the American Society of Nephrology, 1999
- Prospective Study of Hyperhomocysteinemia as an Adverse Cardiovascular Risk Factor in End-Stage Renal DiseaseCirculation, 1998
- Plasma Homocysteine Levels and Mortality in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1997
- Hyperhomocysteinemia: An Independent Risk Factor for Vascular DiseaseNew England Journal of Medicine, 1991